Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug475 | BAY1817080 Wiki | 0.58 |
| drug3226 | Placebo LSF Wiki | 0.50 |
| drug3278 | Placebo tablet Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004715 | Endometriosis NIH | 1.00 |
| D053201 | Urinary Bladder, Overactive NIH | 0.35 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
Study on the safety and tolerability of a new drug BAY2328065 when given increased doses as tablet or solution over 12 days to healthy male participants. Researcher want to study how the body absorbs, breaks down and excrete the new drug, also when given together with a test meal. In addition the study will investigate changes that take place in the body when BAY2328065 is given together with another drug.
It is aimed to measure the general anxiety and lifestyle information of endometriosis patients about covid 19 pandemic, to evaluate anxiety levels in this period.
Description: The Beck Anxiety Inventory (BAI); it measures the frequency of anxiety symptoms experienced by the patient. It consists of 21 questions in total. Each item gets an increasing score between 0-3. The total score ranges from 0 - 63. The following guidelines are recommended for the interpretation of scores: 0 -9, normal or no anxiety; 10 -18, mild to moderate anxiety; 19 -29, moderate to severe anxiety; and 30 - 63, severe anxiety.
Measure: Covid 19 Anxiety levels in Endometriosis Patients Time: 20 daysIn this study, researchers want to find whether the study drug BAY1817080 has an effect on the electrocardiogram (ECG). 40 healthy male or female participants with the age of 18 to 65 years will be enrolled into this study. The ECG of the participants will be monitored closely by the researchers to detect any change after intake of the study medication.
Description: Area under the concentration vs. time curve from zero to 24 hours after multiple doses
Measure: AUC(0-24)md after multiple oral doses of BAY1817080 therapeutic or supra-therapeutic dose Time: Predose and up to 24 hours after last dose of BAY1817080 at Day 3Description: Area under the concentration vs. time curve from zero to infinity after single dose
Measure: AUC after a single oral dose of moxifloxacin Time: Predose and up to 24 hours after single dose of moxifloxacin at Day 3Description: Maximum observed drug concentration in measured matrix after multiple doses
Measure: Cmax,md after multiple oral doses of BAY1817080 therapeutic or supra-therapeutic dose Time: Up to 24 hours after last dose of BAY1817080 at Day 3Description: Maximum observed drug concentration in measured matrix after single dose
Measure: Cmax after a single oral dose of moxifloxacin Time: Up to 24 hours after single dose of moxifloxacin at Day 3The purpose of this study is to assess safety and efficacy of BAY1817080 compared to elagolix and placebo in women with symptomatic endometriosis. Study details include: - Study duration: 155 up to 285 days - Treatment duration: 84 days - Visit frequency: approximately once a month
Description: Endometriosis associated pelvic pain (EAPP) will be measured daily on the numerical rating scale (NRS) ranging from 0 to 10 by item 1 of the Endometriosis Symptom Diary (ESD). The higher number indicates a higher level of pain experience
Measure: Absolute change in mean worst EAPP from baseline to end of intervention Time: At baseline (last 28 days before start of study drug) and at day 57-84 (+3)Description: Any event arising or worsening after the start of study drug administration until 14 days after the last study medication intake
Measure: Number of participants with treatment-emergent adverse events Time: Up to 98 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports